Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020. Conference Call Details Date: Thursday, May 14 Time: 8:30 am Eastern Time Domestic: 855-327-6837 International: 631-891-4304 Conference ID: 10009533 W
GAITHERSBURG, Md., May 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc.. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020.
| Conference Call Details | ||
| Date: | Thursday, May 14 | |
| Time: | 8:30 am Eastern Time | |
| Domestic: | 855-327-6837 | |
| International: | 631-891-4304 | |
| Conference ID: | 10009533 | |
| Webcast: | http://public.viavid.com/index.php?id=139687 | |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.
| Contacts: | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | LifeSci Advisors, LLC | |
| Phone: 240-654-1450 | 617-430-7577 | |
| wbrown@altimmune.com | arr@lifesciadvisors.com |
